ERIC WOBUDEYA
ID: UNCST-2019-R001047
|
Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV
REFNo: HS6555ES
Primary Objectives
Cohort 1 and Cohort 2
• To determine the weight-band dosing of RPT taken as part of the 1HP regimen by evaluating:
⎯ PK RPT exposures among children with and without HIV
⎯ Safety and tolerability of the 1HP regimen among children with HIV while receiving twice-daily DTG and children without HIV through 28 days of dosing
Cohort 2
• To evaluate the effect of RPT taken as part of the 1HP regimen on the PK of DTG
Secondary Objectives
Cohort 1 and Cohort 2
• To evaluate the effect of covariates including age, weight, sex, ethnicity, nutritional status, and HIV-1 status on the PK of RPT taken as part of the 1HP regimen
• To evaluate the safety of the 1HP regimen through 24 weeks of follow-up
• To evaluate the palatability and acceptability of the 1HP regimen
• To evaluate adherence to the 1HP regimen
Cohort 2
• To evaluate the safety and tolerability of twice-daily DTG through 42 days among children with HIV who are receiving 1HP
• To evaluate virologic control (less than 200 copies/mL) at Day 42 among children taking a DTG-based ARV treatment regimen co-administered with 1HP
|
Uganda |
2025-11-04 12:59:17 |
2028-11-04 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Isaac Ssewanyana
ID: UNCST-2020-R014336
|
ConfiSign HIV/Syphilis Combo Self-Test: Evaluation of Clinical Performance and Usability in the hands of untrained users.
REFNo: HS6687ES
Untrained users will either take part in the label comprehension study and results interpretation study (part A) or in the observed untrained user study (part B). Untrained users enrolled for the label comprehension and results interpretation study (part A), shall not participate in the observed user study (part B) and vice versa.,The primary and overall objective of this study is to evaluate the performance and the usability of the ConfiSign HIV/Syphilis Combo Self-Test in the hands of untrained users from a low prevalence HIV region (< 5%) who have no, or limited experience in self-testing. ,
|
Uganda |
2025-10-29 16:22:26 |
2028-10-29 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Specioza Namakula
ID: UNCST-2025-R021710
|
EMPOWERING MOBILITY: Assessing the Impact of Buffalo Bicycles on Refugee and host Communities in Uganda. A case study of Bidi Bidi, Rhino Camp and Palabek refugee settlements
REFNo: SS4566ES
I. To generate data that will support Learning and evidence-based decision making.
II. To provide systematic and objective information for bicycle usage in refugee communities.
III. Generating information that is required to inform advocacy and further bicycle provision for vulnerable communities.
IV. To determine the effectiveness, efficiency and relevance of bicycles in improving accessibility to essential services like education, health and economic empowerment.
|
Uganda |
2025-10-29 16:20:00 |
2028-10-29 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Victor Musiime
ID: UNCST-2021-R013794
|
Enhancing Novel Research for Inflammation and Cognitive Health among Adolescents and Young Adults Living with Perinatally Acquired HIV and Adversity (ENRICH+)
REFNo: HS6607ES
Specific Aim 1: Investigate differences in ID and NCI in demographically matched, virally suppressed PHIV and HHIV, as well as HUU AYA (15-25 years old) in Uganda while controlling for chronic adversities. Hypothesis 1 (H1): Both ID and NCI will be respectively higher in PHIV vs. HHIV vs. HUU AYA. H2: Within the two HIV groups, those with delayed ART initiation and lower nadir CD4 cell count at ART initiation will have higher ID and worse NCI.
Specific Aim 2: Investigate the relationship between ID and NCI in AYA within all three groups (PHIV, HHIV and HUU) controlling for chronic adversities. H3: There will be a positive association between ID and NCI in each group. H4: In a subset of PHIV and HUU AYA with prior repeated measures of ID, worsening trajectories of ID in PHIV across 6 years will be associated with worse NCI.
Specific Aim 3: Investigate the effects of co-occurring adversities (i.e., profiles) on the relationships between HIV, ID, and NCI. H5: Adversity profiles will be more severe respectively in PHIV vs. HHIV vs. HUU. H6: The strength of association between medical and psychosocial (e.g., stigma, mental health) adversities, ID and NCI will be strongest in PHIV vs. HHIV vs. HUU, respectively.
|
Uganda |
2025-10-29 16:07:10 |
2028-10-29 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Henry Mugerwa
ID: UNCST-2019-R000420
|
A5402 An Open-Label, Randomized Controlled Trial of Pramipexole versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD with Mild Neurocognitive Disorder (MND) in Persons with HIV
REFNo: HS6604ES
1.2 Primary Objectives
1.2.1 To compare pramipexole to escitalopram in the treatment of MDD (and comorbid MDD with MND) based on the Beck Depression Inventory-II (BDI-II/BDI-2) total score [Beck 1996] from baseline to week 24.
1.2.2 To evaluate the safety of pramipexole and escitalopram in PWH having MDD (and comorbid MDD with MND) from baseline to week 24.
1.3 Secondary Objectives
1.3.1 To compare pramipexole to escitalopram in the treatment of MDD using MDD caseness, neurocognitive outcomes, and functional status from baseline to week 24.
1.3.2 To compare the depression, neurocognitive, and functional status outcomes in PWH with MDD alone and with comorbid MDD with MND treated with pramipexole versus escitalopram from baseline to week 24.
1.3.3 To compare the impact of pramipexole and escitalopram on all outcomes above by female versus male sex (assigned at birth) from baseline to week 24.
1.3.4 To determine the impact of pramipexole compared to escitalopram on the measure of HIV-1 RNA viral load in the peripheral blood.
1.4 Exploratory Objectives
1.4.1 To characterize associations between escitalopram trough concentrations and treatment efficacy (BDI-II/BDI-2 total score) as well as participant adverse events (adverse event frequency, severity, and discontinuation rates).
1.4.2 To characterize associations between escitalopram trough concentrations and genetic polymorphisms that affect metabolizing enzymes of escitalopram (known metabolizing enzymes include CYP2C19, CYP2D6, and CYP3A4).
1.4.3 To explore associations between cerebrospinal fluid (CSF) concentrations of escitalopram and BDI-II/BDI-2 total score.
1.4.4 To evaluate adverse events potentially related to drug interactions between antiretroviral therapy (ART) and escitalopram and pramipexole, respectively.
1.5 Substudy Objective
1.5.1 CSF Substudy
To compare the impact of pramipexole and escitalopram on biomarker outcomes in a CSF substudy of participants with MDD alone.
|
Uganda |
2025-10-29 16:04:25 |
2028-10-29 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Abel Kakuru
ID: UNCST-2022-R009193
|
Dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone for the prevention of febrile illnesses in children with sickle cell anemia: a double-blind randomized controlled trial
REFNo: HS6294ES
1.
To compare the incidence of all-cause febrile illness among children with sickle cell anemia randomized to receive monthly SP vs. monthly DP+SP.
2.
To compare the incidence of adverse events among children with sickle cell anemia randomised to receive monthly SP vs. monthly DP+SP.
3.
To compare the prevalence of markers of antimalarial resistance, including those associated with SP and DP resistance, among parasitemic children with sickle cell anemia randomized to receive monthly SP vs. monthly DP+SP.
|
Uganda |
2025-10-29 15:55:44 |
2028-10-29 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Jane Kabami
ID: UNCST-2021-R012588
|
Peerled Dynamic Choice HIV Prevention for Women. The Peer-led DCP Study
REFNo: HS6556ES
To refine and pilot test a Peer-led Dynamic Choice HIV Prevention intervention for women at elevated HIV risk in southwestern Uganda
|
Uganda |
2025-10-29 12:53:43 |
2028-10-29 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Hannah Tusabe Not Applicable
ID: UNCST-2025-R022045
|
EXPLORING THE IMPLEMENTATION OF EARLY GRADE READING METHODOLOGY IN UGANDA PRIMARY SCHOOLS
REFNo: SS4540ES
1.3.1 Main Objective
To explore the implementation of Early-Grade Reading Methodology in primary schools in Uganda.
1.3.2 Specific Objectives
To establish the current practices of Early-Grade Reading methodologies by teachers in primary schools in Uganda.
To identify the challenges teachers face in implementing Early-Grade Reading methodologies in their classrooms.
To determine strategies that can be adopted to improve the implementation of Early-Grade Reading methodologies in Ugandan primary schools.
|
Uganda |
2025-10-29 12:51:10 |
2028-10-29 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
richard kasirye
ID: UNCST-2025-R018157
|
Instructional Technologies for Teacher Education at Busitema University: Application of Skills to Practice
REFNo: SS4450ES
The study aims to answer: How do Busitema University’s teacher education alumni apply ICT knowledge and skills in the secondary schools where they teach? What are their experiences in using ICT in their classrooms? How can the university improve the teacher education program to better prepare graduates for technology-enhanced teaching?
|
Uganda |
2025-10-29 12:48:06 |
2028-10-29 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
.jpg)
|
ALEX KAYONGO
ID: UNCST-2019-R001641
|
Clonotyping Airway T-cells to Uncover Microbiome-Specific Inflammotypes in HIV-Associated COPD
REFNo: HS6625ES
Study Aim:
To investigate the airway microbiome-specific inflammotypes in COPD among HIV-infected individuals in a rural Uganda.
Specific objectives
1.To determine, in vitro, the CD4+T-cell clonotypic library specific to airway bacterial species associated with COPD among HIV-infected individuals in rural Uganda.
2.To determine, ex vivo, the microbiome-specific clonotypic landscape of BAL-derived CD4+T cells from a cohort of individuals stratified by HIV and COPD in rural Uganda.
3.To validate airway microbiome-specific inflammotypes among individuals with COPD transitioning from stable disease to exacerbation and back to stable disease.
|
Uganda |
2025-10-29 12:47:04 |
2028-10-29 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
AGNESS NATABA
ID: UNCST-2024-R002018
|
Reclaiming Rights:Bunyoro Kitara Kingdom Women and their Quest for Reparative Justice from British Colonialism
REFNo: SS4501ES
1. To examine how historical injustices faced by women in the Bunyoro Kitara Kingdom during British colonial rule affected their cultural setting.
2. To evaluate existing reparative justice efforts for women in the Bunyoro Kitara Kingdom.
3. To assess how gender-responsiveness the existing reparative efforts are in fostering inclusive justice, healing, and environmental justice for women in the Bunyoro Kitara Kingdom.
|
Uganda |
2025-10-29 12:44:59 |
2028-10-29 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
JACOB BIBOHERE
ID: UNCST-2025-R021298
|
Assessment of CDC Data Triangulation Activities to Enhance Immunization and Vaccine-Preventable Disease Surveillance Programs in Selected African Countries
REFNo: HS6596ES
1.To assess the extent to which data triangulation has been integrated into the existing immunization and/or VPD surveillance staff workload, program processes, and practices at national and sub- national levels.
2.To identify programmatic successes, challenges, enabling factors, and innovations reported by immunization and/or VPD program staff through the application of triangulation analytic tools.
3.To examine the immunization programmatic decisions, actions, and outcomes that have been informed by the use of data triangulation concepts.
4.To explore and identify sustainability strategies and recommendations for ensuring that data triangulation and existing tools remain integrated into routine program activities.
|
Uganda |
2025-10-29 12:42:52 |
2028-10-29 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Shivan Kamugisha Kaitesi
ID: UNCST-2025-R019815
|
Socio-Ecological Systems Assessment of Factors Influencing the Lion population in the
Greater Virunga Landscape
REFNo: NS989ES
1. Develop a population dynamics model for lions in the Greater Virunga Landscape
2. Assess the functionality of lion movement corridors within GVL
3. Examine the impacts of land use and climate change on the suitable habitat for lions
4. Evaluate factors of human-lion conflict and develop strategies for conflict mitigation and coexistence.
|
Uganda |
2025-10-29 12:41:40 |
2028-10-29 |
Natural Sciences |
Non-Clinical Trial |
Degree Award |
|
Michael Harvey
ID: UNCST-2025-R022115
|
HERPETOFAUNAL DIVERSITY AND BASELINE ECOLOGICAL ASSESSMENT IN SELECT SITES OF NORTHERN AND WESTERN UGANDA
REFNo: NS1049ES
• Generate a list of reptiles and amphibians inhabiting Mount Kadam and surrounding areas
• Compare the distributions of reptiles and amphibians across different habitats within the boundaries of the research site.
• Establish a reference collection of vouchered specimens from the reserve in a local international research collection/museum.
• Tabulate baseline ecological data for each species (see data collection for details)
• Involve local community, students, and other stakeholders in survey methods and data recording
• Publish results of survey in peer-reviewed scientific journals
|
USA |
2025-10-24 17:36:31 |
2028-10-24 |
Natural Sciences |
Non-Clinical Trial |
Non-degree Award |
|
DENISH ONGOL OGWANG
ID: UNCST-2025-R022077
|
THE IMPLEMENTATION OF THE PRISONERS’ RIGHT TO VOTE IN UGANDA. A CASE STUDY OF LUZIRA PRISONS, 1995-2021
REFNo: SS4502ES
1. To assess the adequacy of the legal framework for the implementation of prisoners’ right to vote in Uganda.
2. To identify the challenges that Luzira Prisons face in the implementation of the prisoners’ right to vote
3. To develop a framework for the implementation of the prisoners’ right to vote in Uganda.
|
Uganda |
2025-10-24 17:35:10 |
2028-10-24 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Mudarshiru Bbuye
ID: UNCST-2025-R019080
|
EXPLORING THE ASSOCIATION BETWEEN AIR QUALITY AND THE BURDEN OF RESPIRATORY TRACT INFECTIONS IN KAMPALA, UGANDA
REFNo: HS6603ES
General objective
To explore the impact of ambient air pollution on the incidence, prevalence, and severity of respiratory tract infections, and the extent of enforcement of air quality control policies and regulations in Kampala, Uganda, a low-resourced urban setting
Specific Objectives
1.To conduct a systematic review and meta-analysis to quantify the association between ambient air pollution and respiratory tract infections in low- and middle-income countries (LMICs).
2. To characterise the spatial variation in ambient PM2.5 exposure and its correlation with respiratory tract infection health effect among sub-populations in Kampala, Uganda
3.To determine the effect of air quality policies and regulations on the long-term ambient PM2.5 levels and the respiratory tract infections health effects in Kampala, Uganda.
4. To explore the limitations of adaptation and enforcement of air pollution control policies and regulations to reduce the ambient air pollution health effects in Kampala, Uganda.
|
Uganda |
2025-10-24 17:34:12 |
2028-10-24 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Dr. James Wasike Mangeni Byanasaye
ID: UNCST-2020-R008019
|
DENTAL ANTIMICROBIAL STEWARDSHIP IN UGANDA - DEVELOPING AN EVIDENCE BASED
INTERVENTION
REFNo: HS6561ES
Aim: To develop evidence-based, behaviour science informed antimicrobial stewardship intervention aimed at reducing antibiotic prescribing to adult patients for dental issues.
Objectives:
1. To understand the factors that influence antibiotic prescribing by health care practitioners to adult patients for dental issues.
2. To explore the perspectives of patients seeking dental care on the use of antibiotics for dental issues.
3. To explore community stakeholders' perspectives on the use of antibiotics for dental issues
4. To co-produce an evidence-based, behaviour science informed dental antibiotic stewardship intervention for Uganda.
|
Uganda |
2025-10-24 17:32:56 |
2028-10-24 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Deogratius Ssemwanga
ID: UNCST-2025-R021563
|
Performance Evaluation for Diagnostic Tests
REFNo: HS6649ES
Primary Objective
The overall objectives of this performance evaluation are:
• To verify the performance characteristics of new on-the-market NAATs and antigen RDTs.
• To establish well-characterized viral pathogen sera/plasma reference panels to support evaluation efforts and quality assurance.
• To evaluate the performance characteristics of new, on-the-market, EIAs and RDTs (IgA, IgG and IgM).
• To train laboratory and POC staff in biosecurity and the required technical skills to perform diagnostic testing.
Specific Objectives:
• To confirm whether or not a new NAAT complies with the manufacturer’s specifications,
• To determine the performance equivalence of new on-the-market NAATs, including POC devices, using available gold standards (or any other comparatively/equally as good WHO/FDA approved NAAT),
• To determine the performance equivalence of new on-the-market antigen tests against the gold-standard NAAT,
• To determine the sensitivity and specificity of new on-the-market diagnostic EIAs and RDTs against a gold-standard method,
• To evaluate the operational characteristics of new on-the-market immunoassays. Operational utility characteristics that may be considered include;
o ease of performance
o specimen type utility
o inter-reader variability
o reaction endpoint stability
o suitability for use in facilities with limited infrastructure (no/limited electricity, no/limited clean water)
• To document SOPs and train laboratory staff in performing testing using recommended diagnostic tests,
• To establish a repository of well-characterized natural infection and vaccination sera/plasma as well as swabs/extracted RNA to support future evaluation and verification of immunoassays.
• To establish a cohort of natural infection and vaccinated cases in the country whose samples and demographic characteristics will be used to help understand the dynamics of human immunity development to viral infection in order to inform the clinical interpretation of the various diagnostic assays.
|
Uganda |
2025-10-24 17:31:36 |
2028-10-24 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Grace Muzanyi
ID: UNCST-2021-R013731
|
Exploration Of the Correlation Between Active TB Immunological Markers and Sputum Culture: A Cytokine TB (CYTO-TB) Study
REFNo: HS6426ES
Main Objective
1. To explore the correlation of TB immunological markers (IL-2, IL-2Ra, I-P10, MIP-β, MCP-1) and TB sputum cultures at five-time points: before the start of treatment (Month 0), then Months 1, 2, 5, and 6.
Specific Objectives
1. 1. To assess the level of each or a combination of cytokines at the time points of active TB diagnosis, months 1, 2, 5, and 6, and how they relate to sputum culture on liquid (days to positivity) and solid (quantitative colony counts) media
2. 2. 2. To assess the baseline level of each cytokine or a combination and how it correlates with (a) the clinical response to TB treatment at months 1, 2, 5, and 6; (b) the clinical severity, and radiographic extent (severity) of TB disease at diagnosis and end of treatment.
3. 3. To evaluate the differences in the TB cytokine levels between active and latent TB during treatment with ERHZ (for active TB), and 6H (for latent TB), stratified by HIV status
4. 4. To evaluate the TB cytokine levels across three populations of active TB, Latent TB, and TB-exposed healthy volunteers who are TST/IGRA negative
5. 5. To compare the cost-effectiveness of TB immunological markers against sputum culture (standard of care).
|
Uganda |
2025-10-24 17:30:54 |
2028-10-24 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Wilber Sabiiti
ID: UNCST-2024-R016293
|
UNDERSTANDING INFECTIOUS AND NON-INFECTIOUS DISEASE TRENDS IN KANUNGU DISTRICT TO INFORM PUBLIC HEALTH PLANNING AND INTERVENTIONS
REFNo: HS6462ES
1. Determine types and trends of diseases in Kanungu from 2015–2025.
2. Compare quality and quantity of HCF records with MoH’s DHSI data.
|
Uganda |
2025-10-24 17:28:54 |
2028-10-24 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|